AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02846831 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12-day intervention with single-hormone closed-loop strategy
Description: A sensor will be inserted on the day before the start of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.~Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 12 days.
Study NCT02846831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump
Description: Tandem Diabetes Care
Study NCT02846831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring system
Description: Dexcom G5 Platinum
Study NCT02846831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
Study NCT03175978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGF/MTX
Description: 765IGF-MTX is supplied as a 5 ml sterile solution at 4.0 µeq per ml 765IGF-MTX concentration in aqueous 10 mM HCl in a 10 ml glass vial
Study NCT02655133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentaglobin®
Description: Immunoglobulins that will be used are IgM enriched and will be infused at 5 ml/Kg/day for 3 days.
Study NCT02655133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic solution
Description: Physiologic solution will be infused and will be infused at 5 ml/Kg/day for 3 days.
Study NCT02921542 — intervention group
Intervention type: DEVICE
Intervention: Laser Atherectomy
Description: The Turbo-Power is laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).
Study NCT01427881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV
Study NCT01427881 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic PBSCT
Study NCT02465645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Study NCT02465645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol + Simvastatin
Study NCT01590459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-509
Description: 50 mg oral tablet
Study NCT04139460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT-D
Description: After randomization, devices will be implanted as soon as possible (within 2 weeks). The ICD will be programmed with anti-tachycardia pacing and shock therapy as per common praxis.
Study NCT04139460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT-P
Description: After randomization, devices will be implanted as soon as possible (within 2 weeks).
Study NCT00782561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-3019
Description: FG-3019 5 mg/kg IV given over 2 hours every 2 weeks for 8 weeks
Study NCT02369549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micro-particle Curcumin
Description: as described in Arm
Study NCT02369549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Looks, smells, tastes and feels exactly like the Curcumin capsules.
Study NCT00575380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AzaSite Eye Drops
Description: One drop two times a day for two days and once a day for the next five days.
Study NCT00575380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigamox Eye Drops
Description: One drop three times a day for seven days
Study NCT03798340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibratory perturbed task-specific movement training
Description: The perturbation-based pinch task training was conducted with the affected hand placed on the pinch device. The horizontal vibratory perturbation was generated for a total of 20 minutes by two recoil-type actuators with a frequency of 30 Hz and an amplitude of 2 mm, and intermittent exposure (10 s per 30 s). Each training session was divided into eight cycles with a training interval of 2 min per 2.5 min.
Study NCT03798340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional task-oriented facilitation
Description: Reach-to-grasp training and hand release training
Study NCT03798340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensorimotor training
Description: Targeted to goals that are relevant to the sensorimotor facilitation of the patient
Study NCT03798340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor training
Description: Targeted to goals that are relevant to the sensorimotor facilitation of the patient
Study NCT02600208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CliniMACs
Description: Depletion of Alpha Beta T cells in the PBSC graft
Study NCT04335188 — intervention group
Intervention type: OTHER
Intervention: Prospective oberservational registry
Description: Non interventional study.
Study NCT04252287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Description: Participants will receive 100 mg immediate-release, over-encapsulated tablets (as a capsule) orally once daily.
Study NCT04252287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo capsules orally once daily.
Study NCT00456482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide 0.59mg
Description: Fluocinolone Acetonide Intravitreal Implant 0.59 mg
Study NCT00456482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide 2.1mg
Description: Fluocinolone Acetonide Intravitreal Implant 2.1 mg
Study NCT06199960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doustim protocol
Description: In Duostim group, the follicular stimulation will be started with a ﬁxed dose of 150 IU of rFSH and HMG 75 IU for 4 days. Daily administration of a GnRH antagonist will be started when the leading follicle are 13-14mm in diameter and continue until the day of the trigger of the ovulation. Five days after the ﬁrst oocyte retrieval second gonadotropin stimulation will be started identical to the ﬁrst one..
Study NCT01590459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VX-509 matching placebo
Description: 0 mg oral tablet
Study NCT01951937 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Meals
Description: Meals containing salmon
Study NCT01951937 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No fish meals
Study NCT00795145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous, Placebo control for blinding, Normal Saline, Single dose
Study NCT02696629 — intervention group
Intervention type: PROCEDURE
Intervention: upper airway surgery
Description: Uvulopalatopharyngoplasty, concomitant transpalatal advancement pharyngoplasty, nasal surgery or multi-level upper airway surgery
Study NCT02696629 — intervention group
Intervention type: DEVICE
Intervention: Continues positive airway pressure
Description: Participants who are treated with continues positive airway pressure during sleep.
Study NCT02696629 — intervention group
Intervention type: BEHAVIORAL
Intervention: education and follow up
Description: Patients education and follow up:The impact of weight loss, sleep position, alcohol avoidance, risk factor modification and medication effects and follow-up are provided for patients' education.
Study NCT01624558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-line Carbon filter (Vapor-Clean)
Description: Carbon filter placed in anesthesia breathing circuit.
Study NCT01569906 — intervention group
Intervention type: RADIATION
Intervention: Narrowband Ultraviolet B phototherapy
Description: Twice weekly exposures for a total of 24 exposures using a standard phototherapy protocol.
Study NCT03279666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tenaculum replacement
Description: Tenaculum replacement during colposcopic biopsy
Study NCT01871818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined program
Description: Combined program with physiotherapy, endurance training and resistance training
Study NCT01871818 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy in private practice
Description: Physiotherapy in private practice
Study NCT01459549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y choledochojejunostomy
Description: Roux-en-Y choledochojejunostomy must be operated
Study NCT04666337 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided supraclavicular brachial plexus blockade
Description: Ultrasound-guided supraclavicular brachial plexus block was done using an ultrasound machine (Philips; Model: OTD020, AcBel Polytech Inc., Taiwan) with a 5-10 MHz linear probe. The brachial plexus and its relation to the surrounding structures were viewed while the patient was supine and the head turned 45° to the contralateral side. In the supraclavicular fossa, the probe was placed in the coronal plane to visualize the subclavian artery and the brachial plexus in a transverse sectional view. After skin sterilization and local anesthetic administration, an insulated needle was then introduced lateral to the ultrasound probe and parallel to the long axis of the probe. Once the needle penetrated the brachial plexus cluster, the local anesthetic mixture was injected incrementally after negative aspiration for blood or air just next to the artery, then the needle was repositioned to inject on the upper pole of the artery.
Study NCT01981356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: The goal of ACT is to help the patient increase psychological flexibility, a core component of mental health and well-being. ACT teaches clients to be mindfully aware but nonreactive to delusions/ hallucinations and to increase willingness to~experience associated distressing emotions while simultaneously engaging in meaningful behavioral actions.~Patients expand their repertoire of behaviors to live according to their values and to pursue valued goals, thereby increasing adaptive functioning and quality of life.
Study NCT01981356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: All patients admitted to the acute psychiatry unit are administered anti-psychotic and/or other psychotropic medication during their inpatient stay. Patients participate in standard milieu therapy on the unit (group and activities therapies, and individual therapy as needed). Therapy on the unit focuses on psycho-education about illness, symptom identification, mood management techniques, stress reduction, and relapse prevention. Patients also receive unstructured individual therapy and case management as appropriate.
Study NCT02315885 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol administration; Placebo administration
Description: consumption of 3 alcohol doses (2 regular and one placebo) each within 2h on separate days
Study NCT02315885 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol administration; Placebo administration
Description: consumption of 3 alcohol doses (2 regular and one placebo) each within 2h on separate days
Study NCT02180113 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fibroscan® examination
Description: Each patient undergo 1 LSM and at least 1 SSM (2 in more if the patient accept to participate at the ancillary study (intra and inter operator reproducibility of SSM).
Study NCT02876939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No kinesiology tape around the hip, knee and ankle joints
Description: Investigators will demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.
Study NCT01130064 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QAX576
Description: every 3 weeks via intravenous infusion
Study NCT01130064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: every 3 weeks via intravenous infusion
Study NCT02712866 — intervention group
Intervention type: DRUG
Intervention: Vedolizumab
Description: Administration of intravenous Vedolizumab in inflammatory bowel disease patients
Study NCT01066741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homeodent®
Description: Two-minute mouthwash with 5 ml of solution diluted in 125 ml of water, 3 times per day after meals and tooth brushing.
Study NCT01066741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.4% Sodium Bicarbonate solution
Description: Two-minute mouthwash with 125 ml of solution, 3 times per day after meals and tooth brushing
Study NCT01472536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequestration
Description: Students will be sequestered within their residence hall room for 3 days following influenza like illness symptoms.
Study NCT00237107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Curretage
Study NCT03231436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose of 12.5mg bupivacaine
Description: Spinal anesthesia performed with 12,5mg of bupivacaine with 25mcg fentanyl for cesarean section
Study NCT03231436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Height-adjusted dose of bupivacaine
Description: Spinal anesthesia performed with height-adjusted dose of bupivacaine with 25mcg fentanyl for cesarean section
Study NCT02063607 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon lambda
Study NCT02063607 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon lambda
Study NCT02197299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine
Study NCT02795351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Single oral administration of active or placebo one week apart
Study NCT02795351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03648476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICAN
Description: A 6-week group therapy sessions once a week for 90-120 minutes.
Study NCT03648476 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ICAN
Description: A 6-week group therapy sessions once a week for 90-120 minutes.
Study NCT04824196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vestibular visual cues therapy
Description: Pelvic rolling to right and left with head movement and stop first on right side for 3 minutes. Do this exercise in front of the mirrorAnterior, posterior, left, and right rectilinear stimulation activities on a therapeutic ball. Anterior, posterior, left and right rectilinear
Study NCT04824196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: propriocetion exercise
Description: 1. Alternate knee flexion-extension with extended trunk posture using both hands for support.~2. Hip and knee flexion-extension with swiss ball between the back and wall.~3. Hip raises lying with their back on the floor with both legs on the swiss ball. Upper limbs leaning on the floor to help with the exercises. then all exercise are perfomed on gym ball
Study NCT01728584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: NMB will be induced by intravenous (IV) administration of a bolus dose of 0.45 mg/kg rocuronium. NMB will be maintained using rocuronium infusion or additional bolus doses as needed for the management of NMB to the targeted depth according to the assigned treatment condition. - Standard NMB - administration of neuromuscular blocking agent (NMBA) titrated to a depth of blockade at a targeted TOF ratio of 10% (range: TOF count 2-3 to TOF ratio of 20%). - Deep NMB - administration of NMBA titrated to a targeted depth of 1-2 Post Tetanic Counts (PTCs) (range: 1-5 PTC).
Study NCT01728584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insufflation
Description: Insufflation (injection) of carbon dioxide will be used to induce pneumoperitoneum, which is presence of air or gas in the abdominal (peritoneal) cavity.~* Standard insufflation pressure - a starting pressure of 12 mmHg will be used.~* Low insufflation pressure - a starting pressure of 8 mmHg will be used.
Study NCT01728584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: NMB will be reversed with IV administration of 2 or 4 mg/kg sugammadex (depending on the depth of NMB) according to the approved label for sugammadex.
Study NCT00856271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: oral tablets, once daily for 8 weeks
Study NCT00856271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan potassium
Description: capsules, once daily for 8 weeks
Study NCT00795145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid 900 mg
Description: Intravenous, 900 mg linezolid, single dose
Study NCT00795145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid 1200 mg
Description: Intravenous, 1200 mg linezolid, single dose
Study NCT00795145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg
Description: Intravenous, 600 mg linezolid, single dose
Study NCT00795145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400 mg
Description: Oral, 400 mg moxifloxacin, single dose
Study NCT04217148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
Study NCT04217148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
Study NCT04217148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: ATRA, po,10mg bid, for 12 weeks
Study NCT02991560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Description: The exercises consisted of 3 sets with 20 repetitions of wrist and elbow flexion; 2 sets with 10 repetitions of wrist extension strengthening starting with 50% of the maximum strength and density increasing the resistance each week; and finally, 2 sets with 10 repetitions of the wrist flexor and extensor muscle groups comprising 20 sec of stretching and 10 sec of relaxing using the healthy hand.
Study NCT02991560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Physioytherapy
Description: The treatment consisted of a cold pack (enclosed in a moist towel for 12 minutes around the elbow joint), TENS (in an asymmetrical biphasic wave form and burst modulation, current width 150 mms, pulse frequency 5 Hz), and deep transverse friction massage (2 minutes of application to the locally sensitive areas determined through palpation on anterolateral surface of lateral epicondyle) followed by home exercises.
Study NCT02991560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Kinesio tape has been implemented on forearm of the patients for the treatment of lateral epicondylitis
Study NCT02991560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Athletic taping
Description: By athletic taping, similar effects with Kinesio taping were aimed to gain. Considering the McConnel principles
Study NCT04504006 — intervention group
Intervention type: PROCEDURE
Intervention: Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL)
Description: Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL)
Study NCT01866176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stabilizing Knee Brace
Description: Brace with no valgus action
Study NCT01866176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valgus Knee Brace
Description: Valgus brace with traditional three point bending system
Study NCT01866176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Knee Brace
Description: Brace with new mechanism to decrease the knee loading.
Study NCT03566238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250 (odevixibat)
Description: A4250 is a small molecule and selective inhibitor of ileal bile acid transporter (IBAT).
Study NCT03566238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical in appearance to active drug (A4250).
Study NCT00665951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir
Description: Lopinavir/ritonavir 200/50mg; 2 tablets; single dose
Study NCT00665951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Lopinavir/ritonavir 100/25mg; 4 sachets with granules; single dose
Study NCT00665951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Lopinavir/ritonavir 100/25mg; 4 tablets; single dose
Study NCT01847924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MLC901
Description: 24 weeks intervention with orally MLC901. 2 capsules 3 times a day